Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - Cidara Therapeutics (NASDAQ:CDTX) : vimarsana.com

SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed

Related Keywords

Barcelona , Comunidad Autonoma De Cataluna , Spain , San Diego , California , United States , Michael Fitzhugh , Roxanae Rojas , Ruben Faelens , Jeffrey Stein , Brian Ritchie , Lifesci Communications , Cidara Therapeutics Inc , European Society Of Clinical Microbiology , Securities Exchange , Johnson , Exchange Commission , European Society , Clinical Microbiology , Infectious Diseases , Chief Executive Officer , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report ,